ACS Pharmacology & Translational Science · 2022 · 14 citations · 46 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryChemical Library DesignHeterocyclic ChemistryLead Compound DesignLigand-based DesignStructure-activity Relationship AnalysisAnticancer ActivityMedicinal Chemistry ApplicationsMedicinal HeterocyclesMorpholine ChemistryPiperidine ChemistryQuinoxaline ChemistryQuinoxaline SynthesisSelectivity
A novel series of 2-(benzimidazol-2-yl)quinoxalines with three types of pharmacophore groups, namely, piperazine, piperidine, and morpholine moieties, which are part of known antitumor drugs, was designed and synthesized. The compounds have been characterized by NMR and IR spectroscopy, high- and low-resolution mass spectrometry, and X-ray crystallography. 2-(Benzimidazol-2-yl)quinoxalines with N-methylpiperazine substituents showed promising activity against a wide range of cancer lines, without causing hemolysis and showing little cytotoxicity against normal human Wi-38 cells (human fetal lung). A mixture of regioisomers 2-(benzimidazol-2-yl)-3-(4-fluorophenyl)-6(and 7)-(4-methylpiperazin-1-yl)quinoxalines (mriBIQ 13da/14da) showed a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) with a half-maximal inhibitory concentration at the level of doxorubicin with a selectivity index of 12. The data obtained by flow cytometry, fluorescence microscopy, and multiparametric fluorescence analysis suggested that the mechanism of the cytotoxic effect of the mriBIQ 13da/14da on A549 cells may be associated with the stopping of the cell cycle in phase S and inhibition of DNA synthesis as well as with the induction of mithochondrial apoptosis. Thus, mriBIQ 13da/14da can be considered as a leading compound deserving further study, optimization, and development as a new anticancer agent.
46
Progress in Heterocyclic Chemistry
Masaki Ohta · Journal of Synthetic Organic Chemistry Japan · 1958 · 436 citations · Full text
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Taisuke Uehara, Yukinori Minoshima, Koji Sagane et al. · Nature Chemical Biology · 2017 · 379 citations
PML NBs associate with the hMre11 complex and p53 at sites of irradiation induced DNA damage
Roberta Carbone, Mark Pearson, Saverio Minucci et al. · Oncogene · 2002 · 188 citations
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
Pan Pantziarka · ecancermedicalscience · 2015 · 160 citations · Full text
Medicine, Oncology, Pharmacology +17